Publication date: Oct 14, 2024
The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 patients who received nirmatrelvir-ritonavir (NR group) or azvudine (FNC group) at Peking Union Medical College Hospital between 1 November 2022 and 27 February 2023. Patients in the FNC group (n = 304) were younger, exhibited less severe symptoms, started antiviral therapy later, received corticosteroids more frequently, and used tocilizumab less frequently than patients in the NR group (n = 412). Within 28 d of therapy, 40 (9. 7%) and 20 (6. 6%) deaths were in the NR and FNC groups, respectively. No differences were observed between drugs and mortality rates (odds ratio [OR] 0. 78, 95% CI 0. 40-1. 5, P = 0. 45), clinical improvement (OR 0. 79, 95% CI 0. 79-1. 3, P = 0. 38), and clinical progression (OR 1. 0, 95% CI 0. 58-1. 8, P = 0. 96). More patients in the NR group experienced platelet decline than those in the FNC group (17. 6% vs. 8. 9%, P = 0. 034). This study indicated that the effectiveness and safety of azvudine were comparable to those of nirmatrelvir-ritonavir.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Ritonavir |
| disease | MESH | COVID-19 |
| disease | MESH | infections |
| drug | DRUGBANK | Tocilizumab |
| disease | MESH | clinical progression |
| disease | MESH | coronavirus infections |
| disease | IDO | quality |
| drug | DRUGBANK | Oxygen |
| disease | MESH | death |
| disease | IDO | symptom |
| disease | MESH | emergency |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Baricitinib |
| disease | MESH | cardiovascular disease |
| disease | MESH | chronic kidney disease |
| disease | IDO | blood |
| disease | MESH | bleeding |
| disease | MESH | visual hallucination |
| disease | MESH | allergic reactions |
| drug | DRUGBANK | Creatinine |
| pathway | REACTOME | Metabolism |
| disease | IDO | nucleic acid |
| disease | MESH | drug interactions |
| disease | MESH | diabetes mellitus |
| disease | MESH | viral load |
| drug | DRUGBANK | L-Alanine |
| disease | IDO | cell |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Elm |
| disease | MESH | Pneumonia |
| disease | MESH | Influenza |
| disease | MESH | Virus Infection |